Decibel Therapeutics Stock

decibeltx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $132.06MM

Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine.

Register To Buy and Sell Shares

For more details on financing and valuation for Decibel Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Decibel Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Decibel Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Paula Cobb
Chief Operating Officer
John Keilty
Chief Data Sciences Officer
Albert Edge Ph.D
Co-Founder & Scientific Advisory Board Member
Shin-San Michael Su Ph.D
Chief Scientific Officer
Anna Trask
Chief People, Community and Culture Officer
Charles Liberman Ph.D
Co-Founder & Scientific Advisory Board Member
Ulrich Müller Ph.D
Co-Founder & Member of Scientific Advisory Board
Steven Holtzman
Chairman
Leslie Shinobu MD
Chief of Translational Research
Gabriel Corfas Ph.D
Co-Founder & Member of Scientific Advisory Board

Board Members

Craig Muir
Third Rock Ventures
Neil Exter
Third Rock Ventures
Steven Holtzman
Anthony Philippakis MD
GV
Gabriel Corfas Ph.D
Jeffrey Jonas MD
Roger Brown
Ulrich Müller Ph.D
George Scangos Ph.D
Jens Eckstein Ph.D
SR One
Troyen Brennan MD

Frequently Asked Questions About Decibel Therapeutics’ Stock

plusminus
Can you buy Decibel Therapeutics’ stock?
Decibel Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Decibel Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Decibel Therapeutics’ stock?
Yes, you can sell stock of a private company like Decibel Therapeutics. Forge can help you sell your Decibel Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Decibel Therapeutics’ stock price?
Decibel Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Decibel Therapeutics’ private market stock price with Forge Data.
plusminus
What is Decibel Therapeutics’ stock ticker symbol?
Decibel Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Decibel Therapeutics Appoints Healthcare Industry Veteran Christine A. Poon to its Board of Directors
Decibel Therapeutics announces appointment of biopharmaceutical leader Christine A. Poon to its board of directors.
Decibel Therapeutics Raises $55M in Series C Financing |FinSMEs
Decibel Therapeutics, which discovers and develops medicines to treat hearing loss and hearing-related disorders, raised $55M in Series C funding
Updated on: Apr 15, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.